Method of lyophilizing liposomes
Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.
1. A lyophilized gel-phase liposomal composition, which composition comprises:
(a) gel-phase liposomes that exhibit a melting phase temperature (T c ) of at least 37° C. and wherein the liposome membrane of said liposomes comprises no more than 20 mol % cholesterol and at least 1 mol % of a phosphatidylglycerol (PG) or a phosphatidylinositol (PI) or both; and wherein at least two therapeutic and/or diagnostic agents are stably associated with said liposomes wherein at least one of said agents is amphipathic or hydrophilic; and;
(b) a cryoprotectant external to said liposomes; and
wherein said liposomes contain less than 50 mM internal cryoprotectant, and
wherein when said lyophilized gel-phase liposomal composition is reconstituted in a pharmaceutical carrier, the mean diameter of the liposomes is maintained as compared to said composition prior to lyophilization and said agents are substantially retained in the liposomes.
2. The composition of claim 1 wherein said liposome membrane comprises distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG) and cholesterol (CHOL).
3. The composition of claim 1 wherein the liposome membrane comprises 50-80 mol % DSPC or dipalmitoyl phosphatidylcholine (DPPC), 1-20 mol % DSPG or distearoylphospatidylinositol (DSPI) and 1-20 mol % CHOL.
4. The composition of claim 3 wherein the liposome membrane comprises 50-80 mol % DSPC, 1-20 mol % DSPG and 1-20 mol % CHOL.
5. The composition of claim 4 wherein the liposome membrane has the components DSPC:DSPG:CHOL at 7:2:1 mol ratio.
6. The composition of claim 1 wherein the agents are antineoplastic agents.
7. The composition of claim 6 wherein the antineoplastic agents are daunorubicin and cytarabine, or are irinotecan and floxuridine.
8. The composition of claim 1 wherein said encapsulated agents are at a fixed ratio and wherein when said composition is reconstituted said ratio of the agents changes by no more than 25% as compared to said composition prior to lyophilization.
9. The composition of claim 1 wherein the mean diameter of the liposomes increases by no more than 25% after lyophilization and upon reconstitution of said liposomes as compared to said value measured prior to lyophilization.
10. The composition of claim 1 wherein said mean diameter is maintained for at least 6 months upon storage at from 5° C. to 25° C.
11. The composition of claim 1 wherein at least 75% of each agent is retained upon reconstitution of said liposomes.
12. The composition of claim 11 wherein said mean diameter is maintained for at least 6 months upon storage at from 5° C. to 25° C.
13. The composition of claim 1 wherein the size distribution of the liposomes changes by no more than 25% after lyophilization and upon reconstitution of said liposomes.
14. A method to prepare the composition of claim 1 which method comprises subjecting to lyophilization an aqueous medium comprising gel-phase liposomes wherein said liposomes exhibit a melting phase temperature (T c ) of at least 37° C. and the liposome membrane thereof comprises no more than 20 mol % cholesterol and comprises at least 1 mol % of a phosphatidylglycerol (PG) or a phosphatidylinositol (PI) or both; and said liposomes are stably associated with at least two therapeutic and/or diagnostic agents wherein at least one of said agents is amphipathic or hydrophilic and contain less than 50 mM internal cryoprotectant, in the presence of external protectants.
15. The method of claim 14 wherein said aqueous medium comprising said gel-phase liposomes is frozen at a temperature which is below the glass transition temperature (T g ) of said medium.
16. A method to prepare a pharmaceutical composition for administering therapeutic and/or diagnostic agents to a subject which method comprises reconstituting the liposomal composition of claim 1 in a pharmaceutical carrier to obtain a reconstituted composition.
17. The reconstituted composition of claim 16 for use in a method to administer therapeutic and/or diagnostic agents to an animal subject.